Next Article in Journal
Interactions of a Dopamine D1 Receptor Agonist with Glutamate NMDA Receptor Antagonists on the Volitional Consumption of Ethanol by the mHEP Rat
Next Article in Special Issue
Delivery of RNAi-Based Oligonucleotides by Electropermeabilization
Previous Article in Journal
Protein Kinase C Inhibitors as Modulators of Vascular Function and Their Application in Vascular Disease
Previous Article in Special Issue
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers
Open AccessReview

Design of siRNA Therapeutics from the Molecular Scale

Department of Chemical Engineering and Materials Science, Michigan State University, 428 S. Shaw Lane, Room 2527, East Lansing, MI 48824, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(4), 440-468; https://doi.org/10.3390/ph6040440
Received: 24 January 2013 / Revised: 27 February 2013 / Accepted: 13 March 2013 / Published: 25 March 2013
(This article belongs to the Special Issue RNAi-Based Therapeutics)
While protein-based therapeutics is well-established in the market, development of nucleic acid therapeutics has lagged. Short interfering RNAs (siRNAs) represent an exciting new direction for the pharmaceutical industry. These small, chemically synthesized RNAs can knock down the expression of target genes through the use of a native eukaryotic pathway called RNA interference (RNAi). Though siRNAs are routinely used in research studies of eukaryotic biological processes, transitioning the technology to the clinic has proven challenging. Early efforts to design an siRNA therapeutic have demonstrated the difficulties in generating a highly-active siRNA with good specificity and a delivery vehicle that can protect the siRNA as it is transported to a specific tissue. In this review article, we discuss design considerations for siRNA therapeutics, identifying criteria for choosing therapeutic targets, producing highly-active siRNA sequences, and designing an optimized delivery vehicle. Taken together, these design considerations provide logical guidelines for generating novel siRNA therapeutics. View Full-Text
Keywords: siRNA therapeutic; RNAi; liver cancer; siRNA design; delivery vehicle design siRNA therapeutic; RNAi; liver cancer; siRNA design; delivery vehicle design
Show Figures

Figure 1

MDPI and ACS Style

Angart, P.; Vocelle, D.; Chan, C.; Walton, S.P. Design of siRNA Therapeutics from the Molecular Scale. Pharmaceuticals 2013, 6, 440-468.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop